In Alzheimer's disease (AD), the microtubule-associated protein tau is hyperphosphorylated and aggregates into paired helical filaments (PHFs), leading to NFT formation. Previously, we described a cascade of molecular events associated with NFT formation within cortical neurons in AD. Whether similar or different events occur during NFT formation within cholinergic basal forebrain (CBF) projection neurons during the progression of AD remains unknown. The Program Project entitled """"""""Neurobiology of Mild Cognitive Impairment in the Elderly"""""""" provides an outstanding opportunity to extend these findings to an early stage of AD, people who have died with a clinical diagnosis of mild cognitive impairment (MCI). Establishment of this cascade of tau changes is paramount as NFTs provide a window into the tau portion of the neruonal degnerationn in AD and will allow for in vitro modeling to approach a mechanistic understanding of tau pathology and and aggregation. We propose to investigate whether formation of fibrillar pathologies follows a definable sequence of molecular events that directly impact tau's assembly competency through phosphorylation and truncation while other events (tau cleavage by Puromycin-Sensitive Aminopeptidase expression and non-canonical tau isoform expression) inhibit this process in CBF neurons during the early stages of AD. We propose to place tau changes in an overall molecular context within affected CBF neurons by correlating NFT evolutionary states with enzyme and other proteins expression profiles affecting tau association and function. Specifically: 1. We will test the hypothesis that CBF neuron NFT formation occurs in a linear and orderly fashion assayed and ordered by alterations in phosphorylation and truncation events as certain phosphorylation and carboxy-terminal truncation events appear facilitative of NFT formation;2. We will test for the expression of candidate enzyme genes known to stimulate or inhibit tau's ability to form NFTs defined by specific antibodies to phosphoepitopes, conformational states, and C-terminal truncation sites and, 3. We will test the hypothesis that the expression of small tau isoforms lacking the microtubule binding repeats and carboxy termini inhibit tau filament (and hence NFT) formation.
These aims will begin to define the molecular milieu of tau tangle formation and provide insight into regulatory mechanisms involved in controling and/or inhibiting this phenomenon, which are needed to develop new treatments for AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG014449-15
Application #
8377069
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
2014-01-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
15
Fiscal Year
2012
Total Cost
$288,871
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
Tiernan, Chelsea T; Combs, Benjamin; Cox, Kristine et al. (2016) Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport. Exp Neurol 283:318-29
Mufson, Elliott J; Ikonomovic, Milos D; Counts, Scott E et al. (2016) Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behav Brain Res 311:54-69
Rosa, Elyse; Mahendram, Sujeivan; Ke, Yazi D et al. (2016) Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease. Neurobiol Aging 48:135-142
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Mufson, Elliott J; Malek-Ahmadi, Michael; Snyder, Noelle et al. (2016) Braak stage and trajectory of cognitive decline in noncognitively impaired elders. Neurobiol Aging 43:101-10
Strupp, Barbara J; Powers, Brian E; Velazquez, Ramon et al. (2016) Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease. Curr Alzheimer Res 13:97-106
Mizukami, Katsuyoshi; Akatsu, Hiroyasu; Abrahamson, Eric E et al. (2016) Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease. Neuropathology 36:135-45
Gorelick, Philip B; Counts, Scott E; Nyenhuis, David (2016) Vascular cognitive impairment and dementia. Biochim Biophys Acta 1862:860-8
Tiernan, Chelsea T; Ginsberg, Stephen D; Guillozet-Bongaarts, Angela L et al. (2016) Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. Neurobiol Aging 42:80-90
Beck, John S; Mufson, Elliott J; Counts, Scott E (2016) Evidence for Mitochondrial UPR Gene Activation in Familial and Sporadic Alzheimer's Disease. Curr Alzheimer Res 13:610-4

Showing the most recent 10 out of 245 publications